Primary peritoneal papillary serous carcinoma (PPPSC) is an uncommon disease which has a high malignancy and a poor prognosis.
We report here a long-term survival case of PPPSC with postoperative lung metastasis. A 62-year-old female patient with PPPSC was administered two cycles of neoadjuvant chemotherapy (NAC) followed by cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) and six cycles of platinum-based (docetaxel + carboplatin) intraperitoneal chemotherapy postoperatively. The patient reached a complete remission at the completion of primary treatment. Malignant thoracic effusion and lung metastasis developed 5 months after the treatment. The patient underwent video-assisted thoracoscopic surgery plus hyperthermic intrapleural chemotherapy.
Up to present, the patient has been survived with tumor for over 86 months with a good performance status, with only encapsulated effusion found at the latest follow-up. As a relatively new regime, the application of CRS + HIPEC in our patient has been proved example for MPE management, although more large-scale studies are needed to substantiate its efficiency and safety.
Bloss JD, Brady MF, Liao SY, Rocereto T, Partridge EE, Clarke-Pearson DL. Extraovarian peritoneal serous papillary carcinoma: a phase II trial of cisplatin and cyclophosphamide with comparison to a cohort with papillary serous ovarian carcinoma-a Gynecologic Oncology Group Study. Gynecol Oncol. 2003;89:148–54. CrossRefPubMed
Sakakibara Y, Endo S, Yoshida Y, Tanaka Y, Hashimoto T, Ohara T. A case of serous surface papillary carcinoma of the peritoneum metastatic to the brain. No Shinkei Geka. 2011;39:607–10. PubMed
Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, Zhou YF, Xiong B, Yonemura Y, Li Y. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18:1575–81. CrossRefPubMedPubMedCentral
National Comprehensive Cancer Network. (NCCN) Clinical Practice Guidelines in Oncology. Ovarian caner: including fallopian tube cancer, and primary peritoneal cancer, Version 3. 2014. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed 9 May 2014.
Vasudev NS, Trigonis I, Cairns DA, Hall GD, Jackson DP, Broadhead T, Buxton J, Hutson R, Nugent D, Perren TJ. The prognostic and predictive value of CA-125 regression during neoadjuvant chemotherapy for advanced ovarian or primary peritoneal carcinoma. Arch Gynecol Obstet. 2011;284:221–7. CrossRefPubMed
Eisenhauer EL, Sonoda Y, Levine DA, Abu-Rustum NR, Gemignani ML, Sabbatini PJ, Barakat RR, Chi DS. Platinum resistance and impaired survival in patients with advanced primary peritoneal carcinoma: matched-case comparison with patients with epithelial ovarian carcinoma. Am J Obstet Gynecol. 2008;198(213):e1–7.
- Long-term survival of high-grade primary peritoneal papillary serous adenocarcinoma: a case report and literature review
- BioMed Central
Neu im Fachgebiet Chirurgie
Mail Icon II